1. Introduction {#sec1}
===============

Impurity profiling is an important subset of the pharmacological drug development programme. Presence of impurity molecules in the pharmaceutical formulations might influence the therapeutic compliance and even jeopardize the safety and efficacy of drugs. Historically, impurity is any substance that impacts the percentage purity of the matter of interest like an active ingredient or drug material. However, these impurities do not necessarily affect the quality negatively all the time. Having said that, the purity of the active pharmaceutical ingredient (API) would be compromised, notwithstanding whether the impurity has superior pharmacological or toxicological property. Therefore, any foreign material-whether inert, toxic or pharmaceutically superior-must be thoroughly analyzed and accounted for [@bib1]. 3,3\'-(propane-1,3-diyl)bis(7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo \[d\]azepin-2-one) (IVA-9) is an impurity produced during the commercial synthesis of cardiotonic drug Ivabradine. Ivabradine is a negative chronotropic drug which helps to lower heart rate without many adverse effects [@bib2]. The natural pacemaker of the heart, also known as the sinoatrial node, undergoes spontaneous depolarization due to the recurring changes in its membrane potential [@bib3]. Ivabradine functions by controlling the percolation of sodium-potassium ions through the hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels or the 'f' channels. This sodium-potassium current initiates the diastolic depolarization and hence is responsible for the pacemaker current. Ivabradine selectively blocks the ions flow through the HCN channels by physically binding on to these channels and this result in a reduced pacemaker current. A lowered pacemaker current ensures a reduced heart rate, dependent on the drug dosage [@bib4]. Though sufficient information is available about the structure, properties \[[@bib5], [@bib6], [@bib7]\], and estimation techniques \[[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\] of Ivabradine; there is little information available about its impurity molecule IVA-9 ([Fig. 1a & 1](#fig1){ref-type="fig"}b). The spectroscopic and volumetric estimation of the title molecule has been studied recently by the same authors [@bib16]. At times, the exploratory studies of such molecules lead to the development of alternate drug molecules with better pharmacodynamics or help us to assess its toxicity impact. This has prompted the authors to undertake the structural and spectral studies of IVA-9 via experimental and computational approaches to assess the structure-property relationship. The primary screening of the physiochemical properties was also performed to assess and compare the drug-likeness and toxicity effects vis-a-vis the parent drug. The authors are hopeful that these results might help in the future studies wherein IVA-9 could be explored as a potential drug molecule with good pharmacological properties and minimum toxicological impacts.Fig. 1(a): Ivabradine. (b): IVA-9.Fig. 1

2. Materials and methods {#sec2}
========================

3,3\'-(propane-1,3-diyl)bis(7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo \[d\]azepin-2-one) received as a gift sample was used as received. Shimadzu IRSpirit Fourier Transform Spectrophotometer was used for vibrational analysis of the sample between 4000-400 cm^−1^ with a resolution of 2 cm^−1^. Computational studies were performed using Gaussian 09 [@bib17] and Gaussview 06 interface on VMware 8 core virtual CPU (Dell Power Edge R740 server). The optimized geometry, the geometrical parameters, and the vibrational spectrum were computed using Density Functional Theory (DFT) at basis set B3LYP/6-311g. SwissADME, a web-based tool is used to study the physiochemical aspects to assess the drug-likeness and pharmacokinetics of IV-9 [@bib18]. The SwissADME web tool can be accessed freely via <http://www.swissadme.ch>.

3. Results {#sec3}
==========

3.1. Synthetic route for ivabradine and chance formation of IVA-9 as an impurity {#sec3.1}
--------------------------------------------------------------------------------

The routine synthesis of Ivabradine involves the reaction of 7,8-dimethoxy-1,3-dihydrobenzo(d)azepin-2-one (I) with dimethyl formamide to form 7,8-Dimethoxy-3-(3-chloropropyl)-l, 3-dihydro-2H-3-benzazepin-2-one (II) which is then converted to its iodo-derivative (III). The compound III undergoes coupling with (lS)-4,5-Dimethoxy-l-\[(methylamino)methyl\]benzocyclobutane hydrochloride followed by selective hydrogenation to yield Ivabradine ([Fig. 2](#fig2){ref-type="fig"}) [@bib19].Fig. 2Literature method for the synthesis of Ivabradine [@bib19].Fig. 2

Though, IVA-9 was not a listed by-product of this reaction, the possibility of its chance formation as an impurity during commercial synthesis has been described by the following reaction route ([Fig. 3](#fig3){ref-type="fig"}).Fig. 3Suggestive reaction route for the formation of IVA-9.Fig. 3

3.2. Structural elucidation {#sec3.2}
---------------------------

The parent drug Ivabradine is a horse-shoe shaped molecule made up of two unsymmetrical bicyclic moieties ([Fig. 4](#fig4){ref-type="fig"}); first part containing a seven-member lactam unit whereas the latter has a cyclobutane part \[[@bib5]\].Fig. 4Horse-shoe shaped form of Ivabradine (Image Credit: National Center for Biotechnology Information. PubChem Database [@bib20]).Fig. 4

However, the impurity molecule is expected to be different from the parent molecule as it is formed by the dimerization of two lactam bearing segments connected via an alicyclic linkage. The structure is symmetric between two benzazepine units without the tertiary amino nitrogen. Computational modeling has emerged as a powerful tool to elucidate structural and spectral properties of unexplored molecules. The geometry optimization of the molecule was obtained by DFT modeling method using B3LYP/3-21g basis set and the same has been visualized with atom numbering in [Fig. 5](#fig5){ref-type="fig"}. The optimized molecule resembles a hat-shaped structure symmetric between two benzazepine units, unlike the horse-shoe shaped Ivabradine molecule. The benzene ring is distorted a bit as seen by the bond angles 118.9° and 119° at C1 and C6 positions respectively due to the presence of electron-releasing methoxy groups. Further, the methoxy substitution reduces the bond lengths between C1--C2 and C5--C6 to 1.39Å. The lactam chair is expectedly non-planar with bond angles of either 119° or 112° but with an increased bond angle of around 130° at N12. Further, there is a substantial reduction of bond length to 1.37 from 1.5Å between N12 and the beta carbon. There are considerable changes in bond angles at C10--N12--C11 (from 122° to 129.8°), at C10--N12--C13 (from 118.6° to 113.14°), at C11--N12--C13 (from 119.2° to 117°) and at N12--C13--C14 (from 112.2° to 115.4°) compared to Ivabradine molecule. These are presumably due to the replacement of cyclobutane segment by the repeat lactam unit here. The methoxy anisole groups on either side lie in more or less the same plane while the lactam units jut out at around 110° at halfway as shown by the dihedral angles. The apex of the hat made by the aliphatic linkage showed a bond angle of 116°. Out of the four methoxy groups, two (one each on either side) lie in the same plane as the benzene ring while other two (one each on either side) is out of the plane at a dihedral angle of 55° due to the possible torsional strains. The optimized structure visualizes that the lone pair on the lactam nitrogen delocalizes into the lactam ring. This has been corroborated by a short bond length of 1.37Å between N12 and C11. The list of significant dihedral angles is appended in below in [Table 1](#tbl1){ref-type="table"}.Fig. 5Optimized geometry visualized at DFT/B3LYP/6-311g (H atoms being omitted for the sake of clarity).Fig. 5Table 1Consolidated list of Dihedral angles in IVA-9.Table 1Sl. NoDihedralAngle (°)Sl. NoDihedralAngle (°)1C6--C1--C2--C3-0.4940C14--C15--N16--C29-62.342O32--C1--C2--C3177.0941C15--N16--C28--C26-176.583C2--C1--C6--C5-0.3942C29--N16--C28--C267.604C2--C1--C6--O33179.1643C15--N16--C29--C27-178.425O32--C1--C6--C5-177.8144C15--N16--C29--O303.166O32--C1--C6--O331.7445C28--N16--C29--C27-2.707C2--C1--O32--C34127.6146C28--N16--C29--O30178.878C6--C1--O32--C34-54.9347C22--C17--C18--C190.019C1--C2--C3--C40.9548C27--C17--C18--C19-179.7910C1--C2--C3--C9179.1549C18--C17--C22--C210.9611C2--C3--C4--C5-0.5350C18--C17--C22--C26-176.9612C2--C3--C4--C8177.8351C27--C17--C22--C21-179.2313C9--C3--C4--C5-178.8352C27--C17--C22--C262.8514C9--C3--C4--C8-0.4753C18--C17--C27--C29108.8815C2--C3--C9--C10-108.0354C22--C17--C27--C29-70.9316C4--C3--C9--C1070.2055C17--C18--C19--C20-0.9017C3--C4--C5--C6-0.3456C17--C18--C19--O43178.7118C8--C4--C5--C6-178.6557C18--C19--C20--C210.8019C3--C4--C8--C11-73.2558C18--C19--C20--O42178.1120C5--C4--C8--C11105.0759O43--C19--C20--C21-178.8421C4--C5--C6--C10.8060O43--C19--C20--O42-1.5322C4--C5--C6--O33-178.7161C18--C19--O43--C44-3.7023C1--C6--O33--C38-177.6762C20--C19--O43--C44175.9224C5--C6--O33--C381.8563C19--C20--C21--C220.1925C4--C8--C11--N1254.5464C19--C20--C21--C24179.6026C4--C8--C11--O25-123.5865O42--C20--C21--C22-177.2827C3--C9--C10--N12-48.7966O42--C20--C21--C242.1328C9--C10--N12--C11-14.7467C19--C20--O42--C4855.5329C9--C10--N12--C13166.8068C21--C20--O42--C48-127.1330C8--C11--N12--C1011.0669C20--C21--C22--C17-1.0731C8--C11--N12--C13-170.5370C20--C21--C22--C26176.7632O25--C11--N12--C10-170.8971C24--C21--C22--C17179.5433O25--C11--N12--C137.5272C24--C21--C22--C26-2.6334C10--N12--C13--C1461.8773C17--C22--C26--C2869.6635C11--N12--C13--C14-116.8074C21--C22--C26--C28-108.1836N12--C13--C14--C1578.6475C22--C26--C28--N16-61.9037C13--C14--C5--N16-51.4176C17--C27--C29--N1654.1538C13--C14--C5--N16-51.4177C17--C27--C29--O30-127.3839C14--C15--N16--C28121.18

The computed geometrical parameters such as bond lengths and bond angles were then compared with the experimentally obtained results. As no crystallographic data was available for IVA-9 in the literature, we have used the data pertaining to the lactam bearing segment of Ivabradine [@bib21] for comparison. The results showed reasonable agreement between computed and experimental data ([Table 2](#tbl2){ref-type="table"}; Figs. [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}).Table 2Geometrical parameters compared (Computed Vs Experimental [@bib21]).Table 2ParameterComputedExptl (Ref)Bond length (Å)C1--C21.391.37C1--C61.411.40C1--O321.391.38C2--C31.401.41C3--C41.401.39C3--C91.511.52C4--C51.401.41C4--C81.511.52C5--C61.391.38C6--O331.391.36C8--C111.541.52C9--C101.551.51C10--N121.491.46C11--N121.371.35C11--O251.261.23N12--C131.491.50C13--C141.541.53C14--C151.551.51C15--N161.491.50N16--C281.501.46N16--C291.361.35C17--C181.401.41C17--C221.401.39C17--C271.511.52C18--C191.391.37C19--C201.411.40C19--O431.391.38C20--C211.391.38C20--O421.391.36C21--C221.401.41C22--C261.511.52C26--C281.541.51C27--C291.541.52C29--O301.261.23O32--C341.481.35O33--C381.461.41O42--C481.481.35O43--C441.461.41Bond angle (°)C2--C1--C6118.91119.70C2--C1--O32117.45116.4C6--C1--O32123.59123.90C1--C2--C3121.76121.90C2--C3--C4119.15118.92C2--C3--C9123.09125.50C4--C3--C9117.74116.20C3--C4--C5119.67118.30C3--C4--C8118.58116.28C4--C5--C8121.73124.80C4--C5--C6121.12122.30C1--C6--C5119.38119.10C1--C6--O33116.58115.50C5--C6--O33124.04125.40C4--C8--C11111.79116.70C3--C9--C10113.02116.70C9--C10--N12118.61112.50C8--C11--N12119.04117.40C8--C11--O25118.62120.50N12--C11--O25122.31122.40C10--N12--C11129.84122.00C10--N12--C13113.14118.60C11--N12--C13117.01119.20N12--C13--C14115.42112.20C13--C14--C15116.18109.70C14--C15--N16116.13118.60C15--N16--C28113.03118.60C15--N16--C29116.07119.20C28--N16--C29130.79122.00C18--C17--C22119.68116.20C18--C17--C27121.42124.80C22--C17--C27118.91116.28C17--C18--C19121.21122.30C18--C19--C20119.31119.70C18--C19--O43124.10125.40C20--C19--O43116.59116.4C19--C20--C21118.89119.70C19--C20--O42123.46123.90C21--C20--O42117.59116.4C20--C21--C22121.90121.90C17--C22--C21119.00118.92C17--C22--C26118.46116.20C21--C22--C26122.51125.50C22--C26--C28112.32116.70C17--C27--C29114.37116.70N16--C28--C26117.68112.50N16--C29--C27120.45117.40N16--C29--O30120.92122.40C27--C29--O30118.61120.50C1--O32--C34116.82117.60C6--O33--C38117.92117.50C20--O42--C48116.61117.60C19--O43--C44117.87117.50Fig. 6Bond lengths compared (IVA-9).Fig. 6Fig. 7Bond angles compared (IVA-9).Fig. 7

3.3. Vibrational studies {#sec3.3}
------------------------

The solid phase FTIR spectrum was recorded using Shimadzu IRSpirit Fourier Transform Spectrophotometer and the fundamental modes of vibrations were analyzed and interpreted. KBr pellet method was used for sample preparation and the scanning was done between 4000-400 cm^−1^ with a resolution of 2 cm^−1^. The vibrational frequencies were also computed using Gaussian09 with the optimized molecule geometry predicted by DFT at B3LYP/3-21g as the input. The optimized IVA-9 molecule has 69 atoms and 201 possible fundamental vibrations. The computed CH vibrational frequencies are scaled with a scaling factor of 0.966 for better agreement (See Fig. [8](#fig8){ref-type="fig"} (a) & (b); [Table 3](#tbl3){ref-type="table"}).Fig. 8(a): Experimental FTIR spectrum of IVA-9. (b): Computed IR Spectra of IVA-9 @ DFT-B3LYP/6-311g.Fig. 8Table 3Vibrational frequencies and interpretations.Table 3Sl NoWave numberScaled wave NoInt.AssignmentExperimental13201.5113092.79.7Ar CH str Sym23197.2023088.54.1Ar CH str Sym33190.8513082.418.9Ar CH str Sym43188.8373080.412.0Ar CH str Sym53155.3953048.121.4Asymm CH~3~ str63153.9013046.723.5Asymm CH~3~ str73149.8123042.729.1Asymm CH~3~ str83149.0513042.029.6Asymm CH~3~ str93116.0023010.137.2Asymm CH~3~ str103115.9723010.065.1Asymm CH~3~ str113111.7853006.018.2Asymm CH~2~ str (heterocyclic)123107.0483001.414.3Asymm CH~2~ str (heterocyclic)133099.3312994.042.1Asymm CH~2~ str (heterocyclic)143095.2262990.028.4Asymm CH~2~ str153083.8842979.043.2Asymm CH~2~ str163078.5332973.948.8CH~3~ str (terminal)173075.5332971.052.6CH~3~ str (terminal)183054.8632951.073.4Asymm CH~2~ str (heterocyclic)193054.1022950.381.3Asymm CH~2~ str (heterocyclic)203048.5062944.947.1CH~2~ str (ali. link)213042.3722938.912.4CH~2~ str (ali. link)223040.8112937.451.3Sym CH~2~ str (heterocyclic)2910233038.8762935.611.0Sym CH~2~ str (heterocyclic)243038.3672935.115.4Sym CH~2~ str (heterocyclic)253029.1122926.133.1Sym CH~2~ str (heterocyclic)263021.0472918.391.6CH~3~ str (terminal)273018.4412915.8102.8CH~3~ str (terminal)283017.1352914.63.7CH~2~ str (ali. link)293008.442906.262.6CH~3~ str (terminal)303006.9332904.762.6CH~3~ str (terminal)312998.2622896.346.0Sym CH~2~ str (heterocyclic)322996.4422894.653.1Sym CH~2~ str (heterocyclic)332935.1882835.492.3CH~2~ str (ali. link)342906.9042808.157.0CH~2~ str (ali. link)351699.8081642.0486.3C=O str361694.6021637.0477.0C=O str371644.0741588.233.8C--C str (ring)381642.1851586.433.3C--C str (ring)391603.1221548.673.6C--C str (ring)401600.3251545.990.6C--C str (ring)411556.6771503.810.5CH~2~ str (ali. link)421549.8531497.2190.4Scis CH~3~431548.4511495.8155.5Scis CH~3~441545.9431493.481.4Scis CH~3~451545.1621492.667.1Scis CH~3~461543.0051490.51.0Scis CH~2~ (ali)471537.7571485.5265.1Scis CH~3~1650481536.8551484.6319.0Scis CH~3~491531.0531479.017.0Scis CH~2~ (ali)501526.4791474.628.5Scis CH~3~511526.4121474.525.0Bending CH~3~521524.9261473.146.9Scis CH~2~ (heterocy)531522.5551470.836.9Scis CH~2~ (heterocy)541518.3951466.813.6Scis CH~2~ (heterocy)551517.8761466.334.9Scis CH~2~ (heterocy)561516.3271464.841.7Scis CH~2~ (heterocy)1635571516.061464.539.4Scis CH~3~ (ter)581513.3051461.955.6Scis CH~2~ (heterocy)591512.9141461.525.5Scis CH~2~ (heterocy)601497.0371446.113.2OCH~3~ bending611495.8981445.09.8OCH~3~ bending621484.6741434.213.1OCH~3~ bending631483.321432.919.7OCH~3~ bending641433.9631385.217.1CH~2~ wagging651429.6711381.156.6CH~2~ wagging661426.641378.196.0CH~2~ wagging671424.6121376.244.0CH~2~ wagging681405.0851357.3128.7CH~2~ wagging691396.421348.945.7CH~2~ wagging (heterocyclic)1523701383.7941336.712.5CH~2~ wagging (heterocyclic)711379.821332.955.9CH~2~ wagging (heterocyclic)1487721366.7521320.329.9CH~2~ wagging (heterocyclic)731362.7131316.461.4CH~2~ twist1460741354.3921308.330.0CH~2~ twist751351.5281305.614.0CH~2~ wagging (heterocyclic)761348.0451302.229.2CH~2~ wagging (heterocyclic)771336.1811290.89.3CH~2~ wagging (heterocyclic)781334.7961289.410.3CH~2~ wagging (heterocyclic)791323.1811278.294.7CH~2~ out of plane bend1422801316.3881271.623.1CH inplane bend1405811307.1071262.775.1CH inplane bend821305.6631261.3108.4CH inplane bend831304.041259.7591.0CH inplane bend841299.3761255.2698.1CH~2~ out of plane bend851268.981225.816.3CH~2~ out of plane bend861256.8171214.179.7CH~3~ out of plane bend, CH~2~ twist1355871252.0671209.578.0CH~2~ twist881247.4571205.050.9CH in plane bend1317891245.0621202.747.6CH in plane bend901231.011189.2567.8CH in plane bend911224.3291182.799.8CH in plane bend921218.0571176.6140.1CH in plane bend931215.3261174.0346.7CH in plane bend941204.0831163.16.1CH in plane bend951202.9371162.039.6CH in plane bend961202.3611161.556.1CH in plane bend1261971191.7331151.265.9CH~3~ twist981188.3061147.939.6CH~3~ twist991159.1761119.81.8CH~3~ twist1001159.0991119.72.7CH~3~ twist1246.51011154.9381115.725.4CH in plane bend1021153.4541114.223.5CH in plane bend1031146.3051107.348.5CN stretching1222.31041137.0871098.4579.3CN stretching11911051131.1241092.795.0CH~2~ twist1061116.0731078.145.5CN stretching11611071102.7981065.3418.9CH~2~ twist1081102.3241064.8224.9CN stretching1091082.4591045.7646.2CH out of plane bend1101070.671034.3225.2CH out of plane bend1111057.961022.013.8CH out of plane bend1121047.6021012.0206.3CH out of plane bend11051131020.344985.7389.9CH out of plane bend1141017.745983.189.2CH out of plane bend1151007.925973.7188.4CH out of plane bend116993.5127959.710.8CH out of plane bend117986.0881952.616.1OCH~3~ Str1058118981.015947.751.9OCH~3~ Str119973.1914940.1158.4OCH~3~ Str120964.3691931.673.8OCH~3~ Str121935.4415903.6115.5OCH~3~ Str122921.4069890.1105.4OCH~3~ Str123919.4756888.2111.3OCH~3~ Str124918.5779887.355.4CH out of plane bend125912.3955881.410.4OCH~3~ Str1003.8126895.2635864.825.0CH~2~ out of plane bend (heterocyclic)127884.7871854.76.7CH~2~ out of plane bend (heterocyclic)128879.6443849.752.1CH~2~ out of plane bend (heterocyclic)129872.7831843.134.0CH~2~ out of plane bend (heterocyclic)130847.7777819.083.0CH out of plane bend131835.5793807.256.5CH out of plane bend132802.8441775.520.1CH~2~ out of plane bend133794.9082767.927.7CH~2~ out of plane bend (heterocyclic)863134771.6454745.411.0CH~2~ out of plane bend (heterocyclic)135748.4924723.030.1CH~2~ out of plane bend (heterocyclic)136744.2697719.063.8CH~2~ out of plane bend (heterocyclic)830.5137736.1454711.138.0CH out of plane bend138732.2824707.463.0CH out of plane bend139720.3195695.83.0CH bend in plane140710.029685.968.7CH bend in plane141703.002679.119.4CH bend in plane142697.8704674.155.2CH~2~ out of plane bend (heterocyclic)143659.869637.448.7CH~2~ out of plane bend (heterocyclic)144647.6128625.637.0CH~2~ out of plane bend (heterocyclic)145620.7038599.6196.5CH~2~ out of plane bend (heterocyclic)146600.414580.030.6CH~2~ out of plane bend (heterocyclic)147599.2496578.922.4C--C--C in plane bend148590.8451570.8126.6C--C--C in plane bend149536.8585518.6124.3C--C--C in plane bend150528.9297510.916.1C--C--C in plane bend151510.1825492.8120.4C--C--C in plane bend152506.4279489.270.3C--C--C in plane bend153500.1282483.151.7C--C--C in plane bend575154492.2831475.56.9C--C--C in plane bend155481.0087464.716.5C--C--C in plane bend156469.9999454.034.4C--C--C in plane bend157453.2236437.854.3C--C--C in plane bend158444.1604429.110.5C--C--C in plane bend159427.2545412.75.5C--C--C in plane bend160416.7383402.63.0C--C--C in plane bend161400.3562386.76.8C--C--C in plane bend162373.8254361.15.6C--C--C in plane bend163366.7925354.326.7C--C--C in plane bend164357.1741345.036.5C--C--C in plane bend165352.9152340.923.7C--C--C in plane bend166342.067330.439.9C--C--C in plane bend167326.9119315.838.2C--C--C in plane bend168314.4024303.788.3C--C--C in plane bend169299.4024289.223.4C--C--C in plane bend170297.1623287.1132.5C--C--C in plane bend171271.9593262.76.1C--C--C out of plane bend172265.011256.058.5C--C--C out of plane bend173253.7061245.13.8C--C--C out of plane bend174237.5253229.454.4C--C--C out of plane bend175232.2319224.314.9C--C--C out of plane bend176219.7438212.334.2C--C--C out of plane bend177209.9424202.810.2C--C--C out of plane bend178197.4085190.750.4C--C--C out of plane bend179196.6722190.012.6C--C--C out of plane bend180188.5958182.245.7C--C--C out of plane bend181178.1327172.146.9C--C--C out of plane bend182160.2606154.810.8C--CH~3~ in plane bend183153.0272147.85.9C--CH~3~ in plane bend184149.0355144.05.4C--CH~3~ in plane bend185130.7146126.342.8C--CH~3~ in plane bend186109.4655105.723.2C--CH~3~ in plane bend187102.4599.0305.7C--CH~3~ in plane bend188100.245996.893.6C--CH~3~ in plane bend18991.662288.562.4C--CH~3~ in plane bend19089.284886.2181.9C--CH~3~ in plane bend19179.563776.9285.8C--CH~3~ in plane bend19268.242665.9274.5C--CH3 in plane bend19361.622259.578.8C--CH3 in plane bend19460.537858.5115.2C--CH3 in plane bend19553.735851.9155.9C--CH3 in plane bend19646.630645.0482.4twisting19735.793634.6102.7twisting19818.793418.2201.7twisting19914.590614.1194.4twisting20010.68110.3148.5twisting2017.67.386.0twisting

Aromatic CH stretching vibrations are observed between 3100-3000 cm^−1^ \[[@bib22],[@bib23]\] and corresponding in-plane bending vibrations are seen in the range of 1400--1100 cm^−1^ [@bib24]. Theoretical calculations show CH stretching vibrations at 3144.7, 3143.7, 3134.8 and 3134.2 cm^−1^ in-plane bending vibrations at 1319.2, 1315.3, 1297, 1289.6, 1289, 1286.6, 1281.4 and 1268.3 cm^−1^. Though no peaks are observed for CH stretching vibrations in the experimental FTIR spectrum, a characteristic peak at 1317.2 cm^−1^ is seen corresponding to CH in-plane bending. The out of plane bending vibrations are recorded theoretically at 1147.7, 1138.8, 1123.4, 1102.1, 1100.1, 1098.6, 1096 and 1093.1 cm^−1^ while the equivalent experimental value is observed at 1105 cm^−1^.

CO stretching shows up as strong bands between 1850-1600 cm^−1^ and the computed peaks at 1807, 1796, 1778, 1773, 1767, 1743, 1691 and 1658 cm^−1^ are assigned to this. The broad twin peak at 1635 cm^−1^ in the FTIR is ascribed to CO stretching. The corresponding in-plane bending is seen as weak bands at 955 and 925 cm^−1^ whereas the out of plane bending is seen at 786 and 763 cm^−1^ as strong bands. The characteristic peaks for methoxy groups are seen at around 1250 and 1050 cm^−1^. The corresponding peaks are computed at 1289, 1286, 1281, 1268, 1257.8, 1257.7, 1250.5, 1250.4 and 1059, 1057, 1052, 1044, 1039, 1034, 1023, 1001, 999 cm^−1^ respectively. FTIR peaks at 1355, 1313 & 1058, 1003 cm^−1^ are indicative of this. The strong peak at 2849 cm^−1^ in the experimental spectrum is typical of methylene asymmetric stretching in the heterocyclic ring. Same bands are visualized at 2934 and 2841 cm^−1^ in theoretical calculation. The characteristic CN stretching vibrations are visible at 1237, 1194 cm^−1^ and 1227, 1191 cm^−1^ in theoretical and experimental analysis respectively.

3.4. HOMO-LUMO energy gap {#sec3.4}
-------------------------

The energies of frontier orbitals are useful in assessing the chemical reactivity and thermodynamic stability of a system (See Fig. [9](#fig9){ref-type="fig"}). In general, the energies of the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) indicate the electron-releasing and electron-gaining capacities respectively. The HOMO and LUMO energies of 7,8-dimethoxy-1,3-dihydrobenzo(d)azepin-2-one (I) & 7,8-Dimethoxy-3-(3-iodopropyl)-l, 3-dihydro-2H-3-benzazepin-2-one (III), the addition product (IV) and IVA-9 are computed and presented in [Table 4](#tbl4){ref-type="table"}.Fig. 9HOMO-LUMO energy gap.Fig. 9Table 4HOMO-LUMO Energy gap.Table 4CompoundHOMO (eV)LUMO (eV)ΔE (eV)Dipole moment (D)Electronic energy (eV)Compound I-5.83-1.064.773.12-27,170.70Compound III-5.89-1.344.543.37-2,8,844.43Addition product IV-4.91-2.862.052.89-43,499.50IVA-9-5.400.165.561.39-43,572.97

A relatively larger HOMO-LUMO gap of 5.56 eV in IVA-9 is justifiable due to a relatively small aromatic system compared to the reagent compounds and intermediates. Due to this, IVA-9 shows higher kinetic and thermodynamic stability and less chemical reactivity. Further, the lack of conjugation renders the molecule colorless with fewer chances of electronic excitation in the visible range.

The energy gap of 5.56 eV in IVA-9 falls at around 225 nm in the ultraviolet region and the molecule is expected to show strong absorption at this wavelength. This has been cross-checked by performing UV-Visible scan via experimental (using Shimadzu UV-Vis spectrophotometer) and computational Time-Dependent DFT (TDDFT) methods and the results are given below ([Fig. 10](#fig10){ref-type="fig"}).Fig. 10UV-Visible spectrum of IVA-9.Fig. 10

A relatively smaller electronic energy implies good stability of the impurity molecule compared to other reacting intermediates and the possibility of the molecule being carried over along with the active ingredient during commercial synthesis.

3.5. ADME studies {#sec3.5}
-----------------

Safety and efficacy are vital aspects of the drug discovery process. It is important to know how the human body process and reacts to a drug system. A successful drug molecule must reach the target site in the adequate amount and remain there in its bioactive form till its intended biologic actions are performed. The evaluation of parameters such as absorption, distribution, metabolism, and excretion (ADME) are very important in this regard for a potential drug molecule. Drug development pipeline often produces a myriad of impurity and intermediate molecules with a potential drug-like character and toxicity effects. The onus is the investigator to spot the best molecule that could go on to become a potential medicine. SwissADME is a useful tool for this primary level of screening and helps in reducing pharmacokinetics-related failure during clinical trials at a later stage [@bib25]. The output file contains a 2D chemical structure of the compound and bioavailability radar which gives a quick inference about the drug-likeness in a nutshell (Fig. [11](#fig11){ref-type="fig"}). Six parameters namely flexibility, lipophilicity, size, polarity, solubility and saturation and their critical limits are depicted in the bioavailability radar (See [Table 5](#tbl5){ref-type="table"}). SwissADME also provides insights into other pharmacokinetic properties such as human gastrointestinal absorption (HIA), blood-brain-barrier (BBB) permeability, total polar surface area (TPSA) and inhibitor action to important cytochromes, etc.Fig. 11(a) Bio-availability radar-Ivabradine. (b): Bio-availability radar-IVA-9.Fig. 11Table 5Physiochemical parameters of Ivabradine and IVA-9.Table 5ParametersIvabradineIVA-9No. of H bond acceptors66No. of H bond donors00Topological Polar Surface area, TPSA ${\text{([}Å\text{]}}^{2}\text{)}$60.577.5Lipophilicity, $\text{log~\!P}$3.42.99Water Solubility, $\text{log~\!S}$-3.9-4.2GI absorptionHighHighBBB permeantYesNoP-gp substrateYesYesCYP1A2 inhibitorNoNoCYP2C19 inhibitorNoYesCYP2C9 inhibitorNoYesCYP2D6 inhibitorYesYesCYP3A4 inhibitorYesYesSkin permeation, $\text{log}\text{~\!K}_{\text{P}}$ (Cm/S)-7.37-7.31Drug-likenessYesYes

By and large, IVA-9 shows similar physiochemical properties compared to Ivabradine. The cytochrome inhibitory actions are similar in most cases. It has a slightly higher total polar surface area (TPSA) due to the presence of extra polar carbonyl oxygen. This, in turn, results in a lower blood-brain-barrier (BBB) permeability. Overall, both molecules show comparable drug-likeness and medicinal chemistry friendliness indices.

4. Conclusions {#sec4}
==============

The structural, spectral and physiochemical properties of the title molecule were studied. The lattice parameters and IR intensities computed showed reasonable concordance with the experimental results pertaining to the lactam bearing segment of Ivabradine molecule. The prospects of chance formation of IVA-9 impurity during the commercial manufacture of the parent drug were also discussed. A relatively larger HOMO-LUMO gap of 5.56 eV shows higher kinetic and thermodynamic stability and less chemical reactivity. The physiochemical properties of IVA-9 such as lipophilicity, water-solubility, polarity, and saturation are comparable to that of the drug molecule, Ivabradine. However, the bio-availability radar shows IVA-9 relatively more flexible than the parent drug due to its symmetric structure. This could be a factor considering the fact that Ivabradine physically binds to the HCN channels to block the passage of ions. It would be useful to explore the possibility of using the impurity molecule for selective blocking in HCN channels due to the structural appropriateness. As a future scope, the article envisages the toxicity studies of the impurity when present along with the parent drug in pharmacological formulations.
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